Podcasts about antibodies

Broadcast from KSQD, Santa Cruz on 3-12-2026: Dr. Dawn discusses Michael Pollan's critique of MAHA dietary recommendations, agreeing that ultra-processed foods should be avoided but noting the lack of science supporting high saturated fat intake. She acknowledges extra virgin coconut oil as an exception that doesn't raise LDL, and pushes back on the social Darwinism embedded in anti-vaccine, anti-welfare MAHA thinking. Dr. Dawn expresses serious concern about Surgeon General nominee Casey Means, a Stanford-trained physician who dropped out of residency to become a wellness influencer. She objects to Means hawking supplements and glucose monitors for personal profit—conduct she considers unethical for a physician giving medical advice. An emailer from Switzerland shares success managing histamine intolerance by avoiding aged meats, shellfish, fermented foods, and cross-reactive pollens during hay fever season. The game-changer was taking DAO (diamine oxidase) supplements before meals to break down histamine in the gut. Researchers found that blood from pediatricians who worked in children's hospitals for over a decade contains powerful antibodies against RSV—up to 25% more effective than existing treatments—built up through years of constant exposure. Dr. Dawn critiques a study finding 2.5 times more microplastics in prostate tumor tissue than surrounding healthy tissue, noting that fast-growing cancers develop extra blood vessels and would naturally incorporate more circulating plastics. She attributes the 6% rise in late-stage prostate cancer to discontinued PSA screening rather than microplastics. An emailer asks what to do about microplastics already in our bodies. Dr. Dawn says there's no way to remove them, and advises avoiding microwaving in plastic, limiting breaded processed foods, and rinsing well after brushing teeth with plastic bristles. AI analysis of mammograms can now detect breast artery calcification as a marker for cardiovascular disease risk, with severe calcification indicating 3.3 times greater risk of heart attack, stroke, or death. This could identify high-risk women years before cardiac events. Dr. Dawn questions a non-peer-reviewed study presented at an orthopedic meeting found five years of GLP-1 drug use associated with 30% higher osteoporosis risk, 150% higher osteomalacia risk, and increased tendon ruptures—likely from reduced food intake and vitamin D consumption. Twin studies now estimate genetics account for 55% of lifespan variation when separating internal biological causes from external factors. Separately, fathers who showed warmth and responsiveness to 10-month-old babies had children with lower inflammation and better blood sugar regulation at age 7—an effect not seen with mothers' parenting. Grandparents actively involved in childcare showed slower cognitive decline than non-caregiving grandparents. Dancing emerged as the standout physical activity for dementia prevention—combining aerobic exercise, social interaction, music, and motor coordination—with three hours weekly showing observable benefits.

Epidemiologist Yvonne “Bonnie” Maldonado is an expert in vaccine research and public health. Look back centuries, and the story is always the same, she says: Death rates from viruses have plummeted, especially in children and the elderly. And yet, millions of children die each year from vaccine-preventable diseases. Vaccines need a return of public confidence, and that starts with better messaging and greater support of nongovernmental messengers like herself. The bottom line is that vaccines are safe, she says. Vaccines work and we have saved many lives because of them, Maldonado reminds host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Yvonne Maldonado Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Yvonne “Bonnie” Maldonado, a professor of pediatrics, epidemiology and population health at Stanford University. (00:03:01) Career in Vaccines Bonnie shares what led to her career in vaccine research. (00:04:53) How Vaccines Work How vaccines train the immune system to recognize and fight pathogens. (00:06:46) Why Vaccine Responses Vary The variability in immune responses and breakthrough infections. (00:09:22) Risk vs. Benefit in Vaccines How researchers evaluate side effects versus disease severity. (00:11:53) How Viruses Evolve The evolutionary dynamics that shape viral behavior. (00:13:59) Vaccine Boosters Why some vaccines last for life while others require multiple doses. (00:17:14) Herd Immunity How community protection works and why vaccination rates matter. (00:21:22) Vaccine Controversy The controversy surrounding vaccines and what led to it. (00:24:27) Global Vaccine Hesitancy How declining trust and past outbreaks influence vaccination globally. (00:27:07) The Future of Vaccines Why vaccines are essential and how outbreaks shape public response. (00:29:08) Preparing for Future Pandemics How healthcare systems prepare for new threats after COVID-19. (00:30:43) Future In a Minute Rapid-fire Q&A: hope, public trust, and the future of health. (00:32:54) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's an era of breakthroughs in Alzheimer's research, yet for many clinicians, it's also a time of profound uncertainty. We are currently navigating competing definitions of the disease, multiple new biomarkers coming on market seemingly every week, and the clinical rollout of new amyloid antibodies. How do we translate this rapid-fire science into daily practice? On this week's GeriPal podcast, we sit down with dementia experts Halima Amjad, Barak Gaster, and Heather Whitson. We dive deep into: The evolving definitions of Alzheimer's disease.  Does someone have Alzheimer's disease if you have only an abnormal biomarker as defined by the Alzheimer's Association, or is amyloid pathology necessary but not sufficient to define Alzheimer's as per the International Working Group (IWG) recommendations? Where do blood-based biomarkers for Alzheimer's fit into the diagnostic workup, and should they be used at all in primary care?  FYI - here is my take on that question in a recent JAMA IM article titled "The Limited Role of Alzheimer's Disease Blood-Based Biomarkers in Primary Care." What's the role of amyloid antibodies in the care of individuals with Alzheimer's disease, including who to use them on? We covered a lot and discussed some of these resources that you can do a deeper dive on: Blood-based biomarker resources JAMA article on Blood-Based Biomarkers for Alzheimer's Disease: Preventing Unintended Consequences  Alzheimer's Dementia article on Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta-analysis JAMA IM article on The Limited Role of Alzheimer Disease Blood-Based Biomarkers in Primary Care Appropriate use recommendations for amyloid antibodies Donanemab: Appropriate use recommendations  Lecanemab: Appropriate Use Recommendations Primary Care Resources Cognition in Primary Care program A JAGS article on "Large Health System Quality Improvement Intervention Providing Training and Tools to Improve Detection of Cognitive Impairment in Primary Care" Other resources AGS's new online curriculum for Alzheimer's Disease By Eric Widera  

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Marion Falabrègue and Ajai Chari on their papers published in volume 146 issue 24 of Blood. The work of Dr. Falabrègue and colleagues in "Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation" indicates that iron absorption from the apical surface of enterocytes can be modulated through manipulation of the hepcidin-DMT1 interaction, opening new avenues for research and therapeutic manipulation. "Talquetamab plus daratumumab in multiple myeloma" features a phase 1b/2 trial of 65 heavily pretreated patients with MM, where Chari et al combined daratumumab and talquetamab, a GPRC5D-targeting bispecific antibody, reporting depletion of CD38-expressing regulatory T cells following daratumumab and impressive efficacy, with an 80% overall (57% complete) response rate and median progression-free survival of 23.3 months. This regimen is now being evaluated in a phase 3 trial. 

Dr. Alex Marson, MD, PhD, is a professor of medicine at the University of California, San Francisco. We discuss the biology of the immune system and cancer, and everyday choices that can increase or decrease your cancer risk, several of which are surprising but all of which are actionable. We also discuss immunotherapy, including how engineered T-cells can be used to defeat childhood and adult cancers. Dr. Marson explains CRISPR and gene editing to cure diseases, and we address the ethical questions surrounding gene editing in embryos, children and adults. This discussion is for anyone interested in avoiding cancer and/or seeking to understand the science and practical applications of immune- or gene-therapy. Read the show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Alex Marson (00:02:21) Diseases & Current Biological Landscape; AI & Computational Tools (00:05:56) Immune System, Innate vs Adaptive Immune System (00:10:55) Thymus, T Cell Selection; B Cells & Antibodies (00:13:23) Sponsors: BetterHelp & Helix Sleep (00:16:11) Immune System Health, Sleep, Diet; Genes (00:20:56) Childhood Exposure & Allergy Prevention; Autoimmune Reactions (00:25:27) Whole Body Immune Response, Cytokines & Fever; Antibiotics (00:30:51) Cancer; Mutations & Cell Regulation; Smoking, BRCA Mutations, Sunlight (00:38:27) BRAC Mutations, Mutagens, Pesticides (00:42:33) Sponsor: AG1 (00:43:57) X-Rays & Airport Scanners, Carcinogen vs Mutagen, Charred Meat, Food Dye (00:49:34) Immune-Based Cancer Treatment, Checkpoint Inhibitors, CAR T-Cell Therapy (00:59:04) CRISPR, Immunotherapies (01:02:52) Age & Cancer Risk; CAR T-Cells, Targets & Side Effects; Ketogenic Diet (01:08:27) CRISPR Discovery & Mechanism (01:17:06) CRISPR Precision, Risk & Benefit; CRISPR Technology Evolution (01:20:57) Sponsor: LMNT (01:22:17) CRISPR Cell Delivery, Clinical Trials; Treating Early Cancers & Prevention (01:33:47) Liposomes, Engineered Viruses, Lipid Nanoparticles (LNPs), Vaccines (01:39:57) COVID Pandemic & Trust in Science, mRNA Vaccine (01:47:51) Sponsor: Function (01:49:39) Drug Delivery to Cancer, Immunotoxins, T-Cell Engagers; AI Protein Targets (01:55:45) CRISPR Embryo Modification, Ethics; Heritable Gene Editing, Diversity (02:05:42) Deep Sequencing Embryos, Diversity; Overcoming Adversity & Resilience (02:10:44) Upcoming Therapeutics, Autoimmunity & CAR T-Cells, CRISPR & Gene Function (02:17:55) Banking T Cells or iPSCs?, Future of Cell Programming (02:24:41) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Interview with Hannes Vietzen, PhD, author of Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases. Hosted by Cynthia E. Armand, MD. Related Content: Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases

Interview with Hannes Vietzen, PhD, author of Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases. Hosted by Cynthia E. Armand, MD. Related Content: Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases

In today's episode, we spoke with Eric K. Singhi, MD. Dr Singhi is an assistant professor in the departments of general oncology and thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.Antibody-drug conjugates (ADCs) are rapidly emerging as one of the most exciting therapeutic advances in lung cancer. In this episode, Singhi explored how TROP2-directed ADCs are beginning to reshape treatment strategies across both non–small cell and small cell lung cancer.Singhi discussed where these agents currently fit within the treatment algorithm for EGFR-mutant non–small cell lung cancer, including the recent accelerated approval of datopotamab deruxtecan-dlnk (Datroway; Dato-DXd) and the evolving clinical data supporting its use after progression on targeted therapy and platinum-based chemotherapy. He also examined emerging evidence for other TROP2-targeting agents such as sacituzumab tirumotecan (sac-TMT) and what early trial results suggest about response rates and future treatment sequencing.Beyond efficacy, Singhi highlighted the practical considerations oncologists must navigate as ADCs enter routine practice, from managing chemotherapy-like toxicities to monitoring for unique adverse effects such as stomatitis, ocular effects, and interstitial lung disease.In our exclusive interview, Dr Singhi discussed where agents like dato-DXd and sac-TMT may fit in evolving treatment algorithms, the clinical data driving their momentum, and what oncologists should consider as these therapies move closer to routine practice in lung cancer.

The killer mutant snowman plagued by antifreeze RETURNS for one more go at being a carrot or whatever the hell he feels like doing. Antifreeze, Asahi, Antibodies. What? NEXT EPISODE ➟ The Strangers chapter who fucking cares PATREON (BONUS EPISODES, VIDEO CONTENT, AND MORE!) ➟ https://patreon.com/screampodcast SCREAM! SOCIALS: Instagram ➟ https://z-p42.www.instagram.com/screampodcast/ Facebook ➟ https://www.facebook.com/thescreampod/?ref=py_c HORRORMOVIEREQUESTS@YAHOO.COM SCREAMPODCAST@YAHOO.COM HORROR SOUP SOCIALS: Instagram ➟ https://www.instagram.com/horrorsoup/?hl=en YOUTUBE ➟ https://www.youtube.com/c/HorrorSoup LETTERBOXD (MOVIE REVIEW APP) ➟ https://letterboxd.com/horrorsoupcaleb/ ~Music Credits~ ETHAN HURT – WWW.ETHANHURT.COM KYLE HERMAN - @iamkyleherman on Instagram Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this Q&A episode, Dr. Eric answers listener-submitted questions all about thyroid antibodies—what they are, why they matter, and how they impact both Graves' disease and Hashimoto's thyroiditis. He begins by clarifying the three main thyroid antibodies—TPO, TSI/TRAB, and thyroglobulin antibodies—and explains why understanding these markers is critical when assessing true remission.Throughout the episode, Dr. Eric addresses common concerns such as: Can you be in remission if antibodies are still positive? How often should antibodies be tested? Can diet alone normalize them? He also explores the role of environmental triggers, gut health, gluten, iodine, and even supplements like selenium, black seed oil, and low-dose naltrexone (LDN). You'll hear practical guidance on why antibodies fluctuate, what “optimal” really means (not just “within range”), and why many conventional endocrinologists don't routinely monitor these markers.If you're confused about your antibody results—or wondering why you relapsed after being told you were “in remission”—this episode will help you connect the dots. If you want a clearer, more balanced understanding of thyroid antibodies and what they really mean for your recovery, you'll get a lot out of this episode.If you want to subscribe to my free Healing Graves' Naturally newsletter visithttps://savemythyroid.com/GravesNewsletter Free resources for your thyroid healthGet your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.comHigh-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid?Get free access to hundreds of articles and blog posts: https://www.naturalendocrinesolutions.com/articles/all-other-articles Watch Dr. Eric's YouTube channel: https://www.youtube.com/c/NaturalThyroidDoctor/videos Join Dr. Eric's Graves' disease and Hashimoto's group: https://www.facebook.com/groups/saveyourthyroid Take the Thyroid Saving Score Quiz: https://quiz.savemythyroidquiz.com/sf/237dc308 Read all of Dr. Eric's published books: http://savemythyroid.com/thyroidbooks Work with Dr. Eric: https://savemythyroid.com/work-with-dr-eric/

Secreted frizzled-related protein 2 is a protein that helps cancers grow by supporting the formation of new blood vessels, stopping cancer cells from dying, and weakening immune cells that should recognize and attack cancer cells. Dr. Nancy Klauber-DeMore is developing an antibody that blocks this protein. Early research suggests the antibody may halt the growth of triple-negative breast cancer. Listen to the episode to hear Dr. Klauber-DeMore explain: what secreted frizzled-related protein 2 does and why she thought blocking it might help treat breast cancer why she's focusing her work on triple-negative breast cancer the next steps for the antibody she and her team have developed

Featuring perspectives from Dr Hope S Rugo and Dr Sara M Tolaney, including the following topics: Introduction: Long-Term Outcomes with Antibody-Drug Conjugates (0:00) HER2-Positive Breast Cancer (8:02) HER2-Negative Breast Cancer (32:41) CME information and select publications

Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data with antibody-drug conjugates in the management of breast cancer.CME information and select publications here.

In this week's Principles of New Biology webinar, Tom read Chapter 2 of his developing booklet: “Then Something Happened.” He explores the idea that humanity experienced a profound shift in consciousness beginning in the 1600–1700s—moving from a vitalistic, ether-based understanding of life to a mechanical, reductionist worldview.This chapter dives into:– Lost ancient knowledge and hidden history– Electromagnetism and the four elements– What “the catastrophe” was and how we chose it– Healing with ether, light, and sound– How to reclaim meaning, coherence, and true vitalityThe session also included Q&A on:– Trauma and where it's stored– Sick sinus syndrome and restoring heart rhythm– Antibodies, blood types & Rhesus factor– Vitality, frozen shoulder, and modern vehicles– Chemotherapy recovery, Rife machines & scalar healing– Healing approaches to Crohn's and animal careSupport the showWebsites:https://drtomcowan.com/https://www.drcowansgarden.com/https://newbiologyclinic.com/https://newbiologycurriculum.com/Instagram: @TalkinTurkeywithTomFacebook: https://www.facebook.com/DrTomCowan/Bitchute: https://www.bitchute.com/channel/CivTSuEjw6Qp/YouTube: https://www.youtube.com/channel/UCzxdc2o0Q_XZIPwo07XCrNg

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 2: Current and Emerging Role of TROP2-Directed ADCs — Sara M Tolaney, MD, MPH CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 1: Current and Emerging Role of HER2-Directed Antibody-Drug Conjugates (ADCs) — Hope S Rugo, MD CME information and select publications

In a world where AI generated content is at the top of our feeds, it is hard to tell what is real and what isn't. We discuss protoscience, and how living in a fantasy can sometimes be a good thing. Featuring special guest C Z A R I N A of darkTUNES Music Group. Supporting sounds by Vioflesh, ANTIBODY, BINARYDIVISON.SOURCES CZARINA Bandcamp https://czarinaofficial.bandcamp.com/CZARINA Website https://www.czarinaofficial.com/ CZARINA - Dagger In The Heart (official video) https://www.youtube.com/watch?v=QImNyGGkMrg CZARINA - Wonderland (official video) https://www.youtube.com/watch?v=fUIkdlQX3f8 darkTUNES Music Group Artists https://www.darktunes.com/en/artistsI, Robot Interrogation Scene https://www.youtube.com/watch?v=05bGPiyM4jg Imagination: It's Not What You Think. It's How You Think | Charles Faulkner https://www.youtube.com/watch?v=QMu5XLux_GA How Humans Perceived Lightning Throughout Time https://www.discovermagazine.com/how-humans-perceived-lightning-throughout-time-43650Proto-Science: From Divination To Data Science https://niafaraway.com/proto-science-from-divination-to-data-science/ The Kite Experiment, 19 October 1752 https://founders.archives.gov/documents/Franklin/01-04-02-0135The Life of Dolly vet.ed.ac.uk/roslin/about/history/dolly/facts/life-of-dolly The Real Scientific Revolution Behind ‘Frankenstein' https://www.sciencefriday.com/articles/real-scientific-revolution-behind-frankenstein/

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, experts John V. Heymach, MD, PhD, and Anne S. Tsao, MD, MBA, FASCO, FACHE, discuss PD-1/CTLA-4, EGFR/PD-1, and DLL3 targeting bispecific antibodies, with a focus on thoracic malignancies.

On this episode of Good Noise Podcast, I'm joined by Aaron Groom and Kat Doniger from Awful Din to talk about their release ANTIBODY. We get into the ideas and emotions driving the project, the sonic direction of the record, and how this release reflects where the band is right now creatively.Awful Din Socials:Instagram: https://www.instagram.com/awfuldinbk/Facebook: https://www.facebook.com/awfuldinTikTok: https://www.tiktok.com/@awfuldinbkYouTube: https://www.youtube.com/@awfuldinbkApple Music: https://music.apple.com/us/artist/awful-din/1302171929Spotify: https://open.spotify.com/artist/3EoHQc1DNy2yieJSLhr32H?si=72f31cf9efd34c42

Guest: Martin Brenner, Ph.D., Chief Executive Officer and Chief Scientific Officer at iBioCompany: iBio, Inc. (NASDAQ:IBIO)Website: https://ibioinc.com/Martin's Bio:Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Company Description: iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

What if your TSH is “normal,” but your thyroid is still part of the fertility story? In this episode of Cycle Wisdom, Dr. Monica Minjeur breaks down how thyroid antibodies—specifically thyroid peroxidase (TPO) and thyroglobulin antibodies—can impact ovulation, luteal phase health, and early pregnancy, even when standard thyroid screening looks reassuring.Through Isla's story of recurrent miscarriage and persistent thyroid symptoms despite a normal TSH, we explore why antibodies often appear years before overt thyroid disease, how they subtly disrupt hormone signaling, and why they matter so much in restorative reproductive care. You'll learn which labs are frequently missed, how inflammation and autoimmunity affect implantation, and what cycle-timed, nutrition-based, and medical strategies can help stabilize thyroid function long-term.If you've been told “your labs are normal” but your symptoms and cycles say otherwise, this episode will help you move from uncertainty to a clear, personalized plan. Learn more or book a free discovery call at radiantclinic.com.

Swedish biotech Affibody has spent over two decades engineering proteins 1/20th the size of a conventional monoclonal antibody — and CEO David Bejker believes they're perfectly suited to solve one of radioligand therapy's biggest problems: a dangerously narrow target space. Bejker discusses how Affibody's platform combines the selectivity of antibodies with the biodistribution flexibility of small molecules, the science behind its Albumod technology, and how its HER2 imaging and therapeutic programs are translating from animals to humans. He also digs into partnerships with AstraZeneca's respiratory unit and complement-focused Rally Bio, manufacturing advantages of E. coli-based production, and Affibody's long-term ambitions as a commercial-stage company.

John Cumbers returns to the Grow Everything podcast for his fourth appearance to discuss the cutting edge of synthetic biology and the upcoming SynBioBeta 2026 conference. From a man who's been bitten by snakes over 200 times to create universal anti-venom, to the race between the US and China in bio-manufacturing, John reveals why the bioeconomy is reaching an inflection point. We explore how AI is transforming organism design, the $50 million deals being struck for AI models in pharma, and why Chinese bio-manufacturing firms are achieving profitability while Western companies struggle. John also shares his vision for cellular reprogramming and longevity, discusses the controversial rollback of US environmental policy, and explains why the "ChatGPT moment" for biology is closer than we think. Plus, learn about stem cell tissue banks that could revolutionize replacement therapy and why SynBioBeta 2030 will actually happen on the moon.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) - Welcome Back: John Cumbers' Fourth Appearance on Grow Everything(00:01:00) - Death Becomes Her: Longevity on Broadway(00:03:00) - Listening Bars and Ambient Music Experience(00:04:00) - The Peptide Revolution: From Gray Market to Mainstream(00:07:00) - Trump Administration Revokes Clean Air Act: Impact on Biotech(00:12:00) - Biomanufacturing as Economic Development and Climate Solution(00:13:00) - AI, Space, and Solar Energy: Elon Musk at World Economic Forum(00:16:00) - Data Centers in Space: The Future of Energy(00:18:00) - Introducing John Cumbers and SynBioBeta 2026(00:19:00) - The Man Bitten by 200+ Snakes: Universal Anti-Venom Story(00:22:00) - The Schmidt Pain Index and Extreme Science(00:23:00) - History and Evolution of SynBioBeta Over 14 Years(00:25:00) - Bio 500: Big Companies Transforming with Biotech(00:27:00) - Plant-Based Sales Slowdown and Consumer Bio Trends(00:30:00) - Discovery vs. Commercialization: Why 80% of Startups Fail on Execution(00:34:00) - Default Alive Companies: Bootstrapping the Bioeconomy00:36:00) - AI Meets Biology: When's the ChatGPT Moment?(00:39:00) - Sidewinder DNA Assembly: Revolutionary Build Technology(00:42:00) - Design-Build-Test-Learn: Closing the Loop with Self-Driving Labs(00:43:00) - China's Biomanufacturing Dominance: What the West Can Learn(00:49:00) - Free Market Capitalism vs. Centralized Planning(00:52:00) - Should SynBioBeta Take Political Stands?(00:55:00) - Longevity Revolution: Cellular Programming and Stem Cell Banks(00:59:00) - Death Becomes Her and the Market for Living Forever(01:01:00) - AI and Bio: The Singularity is Here(01:03:00) - Human Genome Engineering and the Meta Simulation(01:05:00) - Quick Fire Round: Lantern Bioworks, Moon Conference, and Awards(01:07:00) - Closing: SynBioBeta Discount Code and Final ThoughtsLinks and Resources:Synbiobeta website. Join us! Use code: "Grow Everything" for a discountOneSkinReplacement theory of aging - Jean HebertTopics Covered:synbio, synthetic biology, bioengineering, conferences, networks, biotech, biology, bioliteracy, Bio500, AI and BioHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠Instagram⁠⁠ / ⁠⁠Twitter⁠⁠ / ⁠⁠LinkedIn⁠⁠ / ⁠⁠Youtube⁠⁠ / ⁠⁠Grow Everything⁠⁠Music by: Nihilore Production by: Amplafy Media

In Episode 20 of On AIRR, Dr. Lauren Williamson and Dr. Robert Carnahan, both from Vanderbilt University Medical Center, and Dr. Matthew Vogt, from the University of North Carolina, share extreme stories of sample collection that reveal how cutting-edge therapeutic antibody development depends as much on donor generosity and complex global logistics as on scientific innovation. From dramatic efforts to secure the first U.S. donor samples in the early days of the COVID-19 pandemic, to rescuing lost samples from airport corridors and navigating international politics, these stories highlight the critical timing windows, global coordination, and human collaboration required to develop life-saving therapeutics. Throughout these extraordinary stories runs a thread of human generosity, demonstrating how crisis can bring out the best of human nature. Comments are welcome to the inbox of onairr@airr-community.org or on social media under the tag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast. The episode is hosted by Dr. Ulrik Stervbo and Dr. Zhaoqing Ding.  Announcements and links Lauren Williamson https://www.vumc.org/crowe-lab/person/lauren-williamson-phd  Robert Carnahan https://www.vumc.org/crowe-lab/person/robert-carnahan-phd  Matthew Vogt https://www.vogtviruslab.com  Other: ReVAMPP  https://revampp.org Adaptive Immune Receptor Repertoire Community (AIRR-C) https://www.airr-community.org The Antibody Society (TAbS) https://www.antibodysociety.org AIRR-C Seminar Series: https://www.antibodysociety.org/the-airr-community/airr-community-seminar-series/

Recorded October 31, 2025 In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gerstein & Borun, to unpack one of the most misunderstood and mission-critical areas of life sciences: intellectual property.If you are a biotech founder, scientist, executive, or investor, this conversation is essential listening.We explore what patent prosecution really means, when startups should begin thinking about IP protection, how “freedom to operate” can determine commercial viability, and how emerging AI tools are reshaping the patent landscape.Dr. Neville brings 25+ years of experience guiding university spin-outs, biotech startups, and global pharmaceutical companies through complex patent strategy. She has helped secure patents for FDA-approved drugs and offers a rare dual perspective as both scientist and attorney.In This Episode We Discuss:• The difference between patent prosecution and patent litigation• Why it is never too early for biotech startups to think about IP• The U.S. one-year grace period vs. Europe's stricter disclosure rules• What “Freedom to Operate” really means for commercialization• Antibody patents, CDR regions, and the doctrine of equivalents• How premature disclosure can impact global patent strategy• The real-world back-and-forth of patent office “office actions”• AI-assisted prior art search at the USPTO — opportunity or risk?• How funding cycles influence patent filing decisions• Women in biotech leadership and venture funding disparities• The most rewarding part of protecting life-changing therapiesWe also break down the USPTO's new AI pilot programs designed to modernize patent examination and discuss how artificial intelligence may impact biotech patenting over the next several years.Why This MattersIntellectual property is often the single most valuable asset in a biotech company.Strong IP strategy can unlock funding, partnerships, and market exclusivity.Weak or mistimed IP decisions can permanently limit global opportunity.For founders and scientists: timing, geography, and disclosure discipline matter more than most people realize.About Our GuestDr. Kate NevillePartner, Marshall, Gerstein & BorunPhD in Immunology, JDLinkedIn: https://www.linkedin.com/in/kate-neville-phd/Firm Bio: https://www.marshallip.com/katherine-l-neville-ph-d/Charity Highlight: Girls on the Run ChicagoAn organization building confidence and resilience in young girls through mentorship and athletic achievement.https://www.girlsontherun.org/HostsDr. Chad BriscoeBioanalytical Scientific Leaderhttps://www.linkedin.com/in/chadbriscoe/Gregory AustinDirector, Business Development | Bioanalysishttps://www.linkedin.com/in/gregoryaustin1/If you enjoyed this episode, subscribe to BioTalk Unzipped on Apple Podcasts, Spotify, or your preferred platform and share with a colleague in biotech, pharma, or life sciences innovation.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend!   I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Sami: Hi Dr. Cabral! I am currently doing your 21 day detox. I am loving every second of it. For one of my meals I decided to have red beats as my carb/veggie. I had this for two dinner meals in a row and noticed the redness in my stool showed up the next morning after my second meal and then 48 hours after my second meal. I read online that eating red beats can help display gut transit time. I know red beats normally turn your stool a red/pink color in general. Are red beats a good natural/home remedy to decide gut transit time? Or would something like the blue poop test work best?                                              Larissa: Hello! My patient recently tested positive for EBV VCA IgM antibodies with positive EBV IgG antibodies but negative early EBV antigen and EBNA levels. She is experiencing fatigue. Would you consider this an acute or reactivated infection? Could it be a false positive? Would you treat this? Thank you in advance!      Katrina: As I explore your protocol options and tests, how would having gastric bypass, 22 years ago affect the results to achieve optimal health. Will the products be effective due to potential absorption issues?     Ateba: Hello Dr.Cabral, I've had some bony growth behind my teeth over the last decade. I believe it's called Mandibular Tori. It seems to have grown quite a bit the last few years. My dentist says it's from jaw clenching, which I had during sleep for quite some time, but I've also heard other things (nutrition deficiencies/toxicity's etc). Don't have parasites according to my stool test, just excessive stress. Wondering if you have any recommendations for this condition. God Bless.      Lisa: Hi Dr Cabral! I listen to you daily, thank you for your knowledge and swear by your functional detox a few times a year! I have been waking up recently (about the last year now) with a mouth full of saliva and I'm forced to get up to spit. I sleep really well - straight through the night, yet this is a bit concerning to me. Any ideas?    Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3663 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

This week, we discuss a new antibody-based nasal spray that protects against the flu: how does it work? Plus, the tiny self-replicating molecule that may give clues to the origins of life on Earth, whether we should regulate "mirror life" research, and how bacteria protect oak trees from drought and other stresses... Like this podcast? Please help us by supporting the Naked Scientists

During last year's PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderated by Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, the discussion centered around whether half-life extended peptides will eventually replace multispecific antibodies. Links from this episode:  PEGS Europe  PEGS Synthetic Design Lab Genentech Eli Lilly and CompanyLust for Life Science B.V. 

Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics: Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00) Targeting folate receptor alpha with mirvetuximab soravtansine (3:59) Targeting TROP2 with ADCs (9:12) Targeting folate receptor alpha with ADCs (14:17) Targeting cadherin-6 with ADCs (17:27) Targeting HER2 with ADCs (26:12) Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)  CME information and select publications

Featuring an interview with Dr Kathleen N Moore, including the following topics: Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00) Comparing toxicities of conventional chemotherapy and ADCs (6:26) Potential of ADCs as maintenance therapy for ovarian cancer (11:35) Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10) Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46) Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22) Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57) CME information and select publications

Dr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on available and novel treatment strategies with antibody-drug conjugates for ovarian cancer.CME information and select publications here.

Why do so many people still feel hypothyroid when their labs look "normal"? In this episode of Thyroid Answers, Dr. Eric Balcavage completes the thyroid lab conversation by addressing three of the most misunderstood tests in thyroid care: reverse T3, T3 uptake, and thyroid antibodies. You'll learn: What reverse T3 actually represents—and why it rises or falls Why high reverse T3 does not mean blocked T3 receptors How T3 medication lowers reverse T3 by suppressing T4, not by improving physiology What the T3 uptake test measures and why it still matters Why free T4 and free T3 can be misleading without total hormone levels How binding proteins, estrogen, liver function, inflammation, and medications affect interpretation What thyroid antibodies do—and do not—tell us about thyroid damage and disease activity This episode is essential listening if you've been told your thyroid is "optimized," yet symptoms persist—or if you're trying to understand why thyroid medications work for some people and cause instability for others. This discussion sets the stage for the February series on thyroid medication physiology, including T4-only therapy, T3 therapy, combination therapy, and desiccated thyroid.

Thyroid issues can feel confusing — especially when you're told your TSH is “off,” you have antibodies, or you're prescribed medication without fully understanding what's going on. The Lanby's Dr. Stephanie Wallman, Medical Director, breaks down what thyroid dysfunction actually means, how to interpret your labs, and how to support your thyroid with a root-cause, whole-body approach.On this “One Take on One Take” episode:Tip 1: Understand what your TSH, Free T3, Free T4, and thyroid antibodies really mean — and why TSH alone doesn't tell the full story.Tip 2: Learn how gluten, iodine imbalance, stress, and toxin exposure can trigger or worsen thyroid dysfunction and autoimmune thyroid conditions.Tip 3: Know when lifestyle, nutrition, and stress optimization are enough — and when thyroid medication like Synthroid may be appropriate as part of comprehensive care.Subscribe to Get Well Better by The Lanby: Apple Podcasts: https://podcasts.apple.com/us/podcast/get-well-better Spotify: https://open.spotify.com/show/get-well-better YouTube: @TheLanby Or search “Get Well Better by The Lanby” on your favorite podcast platform!VISIT THE LANBY: Explore membership and learn more about The Lanby's functional medicine approach:https://www.thelanby.comFOLLOW THE LANBY ON SOCIAL: Instagram: https://www.instagram.com/thelanby Tiktok: https://www.tiktok.com/@thelanby LinkedIn: https://www.linkedin.com/company/thelanbySTAY IN THE KNOW: Subscribe to The Lanby newsletter for health tips, podcast drops, and expert insights: https://www.thelanby.com/newsletter

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into the multitude of changes and advancements sweeping across the industry, each with profound implications for drug development, patient care, and market dynamics.The pharmaceutical landscape continues to transform as companies like Daiichi Sankyo make significant progress with antibody-drug conjugates (ADCs). Their collaboration with AstraZeneca on products like Enhertu and Datroway represents a robust push into earlier lines of therapy. This strategic move aligns with a broader industry trend where ADCs are being positioned as front-line oncology treatments. These therapies are lauded for their targeted delivery mechanisms that maximize therapeutic efficacy while minimizing off-target effects. However, the competitive landscape is becoming increasingly fierce, necessitating robust clinical data to stand out in this rapidly evolving market segment.Elsewhere, Moderna's recent decision to pause new late-stage trials for infectious disease vaccines highlights the intricate interplay between public sentiment and corporate strategy. The rising anti-vaccine sentiment in the U.S., compounded by diminishing support infrastructure from previous administrations, has significantly influenced Moderna's strategic recalibration. This situation underscores a critical challenge for developers of mRNA platforms: how to navigate complex public perceptions and policy landscapes while pushing forward with vaccine innovations.From a regulatory perspective, Recipharm's commissioning of a new facility in Bengaluru, India for non-bacterial beta-lactam drugs aligns with evolving FDA standards. This investment is not just about compliance; it's a proactive adaptation to meet rising customer demand and represents a strategic partnership with a major biopharmaceutical player. Such collaborations are crucial as they help scale drug production capabilities effectively.The dissolution of the marketing partnership between Arcutis and Kowa over Zoryve reflects the ever-dynamic nature of commercial collaborations within the industry. Originally intended to broaden Zoryve's market beyond dermatologists to include primary care physicians, this shift may indicate strategic realignments or divergent priorities between partners. Such changes can significantly impact market penetration strategies and highlight the importance of aligned goals within partnerships.In Europe, regulatory expansion by GSK of its Arexvy vaccine for all adults marks a pivotal milestone in widening access to crucial vaccines. This development not only enhances GSK's market presence but also underscores the agility required in regulatory responses to public health needs.On the financial front, settlements under the False Claims Act reaching $6.8 billion in FY2025 demonstrate heightened scrutiny on compliance practices within the industry. This serves as a stark reminder of both financial and reputational risks tied to non-compliance and underscores an ongoing need for stringent oversight mechanisms.Amidst economic uncertainties, AstraZeneca's decision to pause its UK research site investment reflects broader industry challenges related to strategic reallocations of resources. Companies are increasingly re-evaluating their geographic footprints and investment priorities in response to evolving market conditions.In precision oncology, Guardant Health's FDA approval for its Guardant360 CDx test in conjunction with Pfizer's Braftovi highlights how companion diagnostics are becoming integral in enhancing therapeutic outcomes through tailoring treatments based on specific genetic profiles. These developments illustrate a multifaceted landscape where scientific innovation, regulatory changes, strategic partnerships, and compliance considerations converge.The recent landscapSupport the show

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) ⁠⁠⁠ from the Immunology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics:  Introduction (0:00) Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24) Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10) Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO (14:54) Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — Prof Dickinson (18:00) Case: A woman in her mid 50s with multiregimen-recurrent follicular lymphoma (FL) receives mosunetuzumab — Carla Casulo, MD (35:33) Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab with an ongoing complete response — Dr Sehn (40:05) FL and Other NHL Subtypes — Dr Sehn (45:30) CME information and select publications

Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here.

If you've ever wondered whether your thyroid questions are too specific or if anyone else is dealing with the same confusion this episode is for you.In this Q&A episode, I answer a mix of situational and common thyroid health questions submitted by listeners with Graves', Hashimoto's, and other thyroid conditions. We cover topics like thyroid antibodies, lab interpretation, medication decisions, iodine, fatigue, hair loss, nodules, and lifestyle factors such as fasting and gut health. Some questions are very individual, while others apply broadly and can help you better understand your own labs and symptoms. My goal is to give you context not one-size-fits-all answers, so you can make more informed decisions about your next steps.If you've been asking yourself, “Does this apply to me?” or “Why hasn't this been explained clearly before?”, tune in and see which of these questions helps bring clarity to your own thyroid journey.Episode Timeline: 00:04 – Episode Overview 01:40 – Antibodies and Thyroid Eye Disease03:35 – T3 vs T4 Medications05:45 – Hyperthyroidism vs Graves Disease07:05 – When Thyroid Meds Don't Help09:09 – Fluctuating Hyper and Hypo Labs11:40 – Hyperparathyroidism and Surgery Questions15:55 – Thyroid Ablation: Risk vs Benefit18:32 – What Triggers Graves Disease22:10 – Iodine: Helpful or Harmful?26:10 – Hair Loss and Thyroid Imbalance27:34 – Preventing Postpartum Thyroiditis30:10 – Intermittent Fasting and Thyroid Health33:00 – Gut Testing: Is It Worth It?36:30 – Thyroid Nodules and Treatment Options40:15 – High Cholesterol and Thyroid Issues42:40 – Can You Stop Thyroid Medication?45:10 – Normal TSH, Still SymptomaticTo take the Save My Thyroid Quiz visit www.savemythyroid.com/quiz Free resources for your thyroid healthGet your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.comHigh-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid?Get free access to hundreds of articles and blog posts: https://www.naturalendocrinesolutions.com/articles/all-other-articles Watch Dr. Eric's YouTube channel: https://www.youtube.com/c/NaturalThyroidDoctor/videos Join Dr. Eric's Graves' disease and Hashimoto's group: https://www.facebook.com/groups/saveyourthyroid Take the Thyroid Saving Score Quiz: https://quiz.savemythyroidquiz.com/sf/237dc308 Read all of Dr. Eric's published books: http://savemythyroid.com/thyroidbooks Work with Dr. Eric: https://savemythyroid.com/work-with-dr-eric/

Communion After Dark - features the latest and best in Dark Alternative-Electronic Music. This week's show features music from Lord of the Lost, Ladytron, Antibody, Grendel, BlakLight, Dulce Liquido, and many more artists from around the world. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process. Structural biology and high-throughput data generation are now collapsing that haystack, offering unprecedented visibility into the molecular handshake that drives life: protein-protein interactions.In this episode, David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, for an in-depth discussion on protein-protein interactions and how advances in data generation and machine learning are transforming antibody discovery and drug development.Troy Lionberger shares his journey into biotechnology, challenges long-held beliefs about antibody development, and explains how Alphabio's high-throughput affinity measurements are shortening timelines and improving outcomes for therapeutic development.In this episode, you'll learn about:The historical and current challenges in characterizing these interactions at scale (06:22)How new technologies—especially high-throughput platforms—are changing the needle-in-the-haystack approach (08:40)A comparison of traditional in vivo and in vitro antibody discovery methods, along with their strengths and limitations (09:06)The evolving role of AI and machine learning in antibody discovery and lead optimization (12:11)Real-world examples of how A-Alpha Bio's approach is compressing years of work into months without sacrificing quality (13:58)The science behind A-Alpha Bio's AlphaSeq technology and how it leverages yeast display and genomics for large-scale affinity measurements (20:43)The practical affinity range the technology can measure, covering most therapeutic applications (23:25)Whether you're a scientist navigating CMC or a biotech professional curious about next-generation workflows, this episode offers practical insights into both traditional and emerging methodologies in the field.Connect with Troy Lionberger:LinkedIn: www.linkedin.com/in/troylionbergerA-Alpha Bio website: www.aalphabio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Featuring perspectives from Dr Javier Cortés, Dr Rita Nanda, Prof Peter Schmid and Dr Priyanka Sharma, including the following topics:  Introduction (0:00) Case: A woman in her early 80s with multiple comorbidities and triple-negative breast cancer (TNBC) develops bone-only metastases 4 months after declining capecitabine for post-neoadjuvant residual disease — Justin Favaro, MD, PhD (1:50) Case: A woman in her mid 70s with ER-negative, HER2-low (IHC 1+), PIK3CA-mutated, PD-L1-positive metastatic breast cancer (mBC) after receiving 3 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab, which was discontinued — Alan Astrow, MD (6:47) Previously Untreated Metastatic TNBC (mTNBC) — Prof Schmid (10:47)  Case: A woman in her early 80s with multiregimen-recurrent ER-positive, HER2-low (IHC 1+) ESR1-mutant mBC receives sacituzumab govitecan — Jennifer Yannucci, MD (27:19) Case: The role of datopotamab deruxtecan (Dato-DXd) for patients with ER-positive, HER2-low mBC who experienced disease progression on prior trastuzumab deruxtecan (T-DXd) — Ranju Gupta, MD; Case: A woman in her late 70s with bilateral recurrence in the lungs of ER-negative, HER2-low (IHC 1+) breast cancer (PD-L1 TPS 20%) receives Dato-DXd with durvalumab on protocol — Yanjun Ma, MD, PhD (31:35) Integrating Antibody-Drug Conjugates (ADCs) into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Sharma (36:31) Case: A woman in her early 70s with recurrent ER-negative, HER2-low (IHC 2+) mBC receives sacituzumab govitecan and achieves complete remission — Dr Gupta; Case: Management of neutropenia associated with sacituzumab govitecan — Gigi Chen, MD (50:30) Case: A woman in her late 60s with recurrent ER-negative, HER2-low (IHC 1+) mBC (HER2 V69L mutation) receives T-DXd and achieves a complete response but develops Grade 1 interstitial lung disease — Dr Gupta; Case: Management of T-DXd-related side effects — Laila Agrawal, MD (54:10) Selection and Sequencing of Therapy for Relapsed/Refractory mTNBC — Dr Nanda (58:59) Case: A woman in her early 40s with multiregimen-recurrent ER-positive, HER2-low mBC who has experienced severe nausea with past treatments is about to initiate T-DXd — Atif M Hussein, MD, MMM (1:12:40) Tolerability and Other Practical Considerations with ADCs and Other Cytotoxic Agents for mBC — Dr Cortés (1:18:10) CME information and select publications

Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.CME information and select publications here.

Let's take a moment to be in awe of breastmilk

In this episode, we're revisiting some of the most magical moments and scientific milestones of 2025 - including the incredible legacy of Dame Jane Goodall, the brain-wave reading bionic-knee, why labradors are so greedy, and the beer that doesn't give you a hangover... Like this podcast? Please help us by supporting the Naked Scientists